NEYRODEGENERATIV KASALLIKLARNING PATOGENETIK MEXANIZMLARI: ALTSGEYMER VA PARKINSON KASALLIKLARI MISOLIDA

Authors

  • Nishonov Muhammaddiyor Kuziboyevich Eurasian multidisciplinary university 2-kurs talabasi

Keywords:

neyrodegenerativ kasalliklar, Altsgeymer kasalligi, Parkinson kasalligi, patogenez, neyroyallig‘lanish, oksidlovchi stress.

Abstract

Neyrodegenerativ kasalliklar markaziy asab tizimining progressiv va qaytarilmas shikastlanishi bilan tavsiflanib, kognitiv, harakat va psixoemotsional buzilishlar bilan namoyon bo‘ladi. Ushbu kasalliklar orasida Altsgeymer va Parkinson kasalliklari eng ko‘p uchraydigan va ijtimoiy ahamiyatga ega bo‘lgan shakllar hisoblanadi. Mazkur maqolada Altsgeymer va Parkinson kasalliklarining rivojlanishida ishtirok etuvchi asosiy patogenetik mexanizmlar zamonaviy ilmiy manbalar asosida batafsil tahlil qilingan. Tadqiqotda oqsil agregatsiyasi, oksidlovchi stress, mitoxondrial disfunksiya, neyroyallig‘lanish va genetik omillarning neyronlar nobud bo‘lishidagi roli yoritilgan. Shuningdek, ushbu mexanizmlarning o‘zaro bog‘liqligi va kasalliklarning klinik kechishiga ta’siri ko‘rib chiqilgan. Neyrodegenerativ kasalliklar patogenezini chuqur o‘rganish erta tashxis qo‘yish, samarali davolash usullarini ishlab chiqish va individual profilaktika choralarini qo‘llash uchun muhim ilmiy ahamiyatga ega.

References

Alzheimer’s Association. Alzheimer’s disease facts and figures // Alzheimer’s & Dementia. – 2023.

World Health Organization. Dementia: A public health priority. – Geneva, 2022.

Selkoe D.J., Hardy J. The amyloid hypothesis of Alzheimer’s disease // EMBO Molecular Medicine. – 2016.

De Strooper B., Karran E. The cellular phase of Alzheimer’s disease // Cell. – 2016.

Lane C.A., Hardy J., Schott J.M. Alzheimer’s disease // European Journal of Neurology. – 2018.

Bloom G.S. Amyloid-β and tau: the trigger and bullet in Alzheimer’s disease pathogenesis // JAMA Neurology. – 2014.

Serrano-Pozo A., Frosch M.P., Masliah E., Hyman B.T. Neuropathological alterations in Alzheimer disease // Cold Spring Harbor Perspectives in Medicine. – 2011.

Heneka M.T. et al. Neuroinflammation in Alzheimer’s disease // The Lancet Neurology. – 2015.

Ashina M. Parkinson’s disease: pathophysiology and clinical aspects // New England Journal of Medicine. – 2020.

Kalia L.V., Lang A.E. Parkinson’s disease // The Lancet. – 2015.

Spillantini M.G., Schmidt M.L., Lee V.M.Y., Trojanowski J.Q. Alpha-synuclein in Lewy bodies // Nature. – 1997.

Dauer W., Przedborski S. Parkinson’s disease: mechanisms and models // Neuron. – 2003.

Surmeier D.J., Obeso J.A., Halliday G.M. Selective neuronal vulnerability in Parkinson disease // Nature Reviews Neuroscience. – 2017.

Exner N., Lutz A.K., Haass C., Winklhofer K.F. Mitochondrial dysfunction in Parkinson’s disease // EMBO Journal. – 2012.

McGeer P.L., McGeer E.G. Inflammation and neurodegeneration in Parkinson’s disease // Parkinsonism & Related Disorders. – 2004.

Hirsch E.C., Hunot S. Neuroinflammation in Parkinson’s disease // Journal of Neurochemistry. – 2009.

Jenner P. Oxidative stress in Parkinson’s disease // Annals of Neurology. – 2003.

Schapira A.H.V., Olanow C.W. The pathogenesis of Parkinson disease // Movement Disorders. – 2004.

Gauthier S. et al. Alzheimer’s disease: clinical management and therapeutic perspectives // The Lancet Neurology. – 2016.

Reitz C., Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers // Biochemical Pharmacology. – 2014.

Downloads

Published

2026-02-13

How to Cite

Nishonov Muhammaddiyor Kuziboyevich. (2026). NEYRODEGENERATIV KASALLIKLARNING PATOGENETIK MEXANIZMLARI: ALTSGEYMER VA PARKINSON KASALLIKLARI MISOLIDA. IQRO , 20(01), 582–580. Retrieved from https://www.wordlyknowledge.uz/index.php/iqro/article/view/5200